Fireside Chat Series 2023
|
||
|
|
The Evolving Carotid Market : One Year Later (Dr. Chris Metzger) |
|
|
CMS Decision adding Standard Risk to Reimbursement (Dr. Kenneth Rosenfield) |
||
|
|
Carotid Market Changes, “A Win for Patients” (Dr. Sean Lyden) | |
|
|
Vascular Surgeon’s Perspective, “Better options for patients” (Dr. Pat Muck) | |
|
|
Shared Decision Making “‘What’s best for the patient is now possible” (Dr. Chris Metzger) | |
|
|
“More stenting will be come a reality” (Dr. Sean Lyden) | |
|
|
“Carotid Stenting, One and done and durable therapy” (Dr. Kenneth Rosenfield and Dr. Chris Metzger) | |
| InspireMD’s investment in an implant first approach with broadest tool set in both CAS and TCAR (Marvin Slosman) | ||
| “TCAR grows with a better CGuard implant” (Dr. Pat Muck) | ||
| “Implant matters and TCAR and CAS win” (Dr. Sean Lyden) | ||
| Market Change. Future Trend toward Stenting, (Dr. Sean Lyden) | ||
| Results from CGuard are Outstanding (Dr. Chris Metzger) | ||
| Fast Forward another year (All) | ||
| Closing Remarks (Marvin Slosman) | ||
Fireside Chat Series 2022
|
||
|
|
Section 1: Introduction |
|
|
|
Section 2: Market Overview |
|
|
|
Section 3: Surgery to Stenting | |
|
|
Section 4: Right Tech, Right Time | |
|
|
Section 5: CGuard™ Advantage in Acute Stroke | |
|
|
Section 6: CGuard™ Moves Towards Standard of Care | |
|
|
Section 7: Next Generation: CGuard Prime™ | |
| Section 8: Wrap Up | ||